The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is
Fears of border delays and complications in a post-Brexit UK have led to the French pharmaceutical company increasing its contingency stockpiles by four weeks to enable a 14-week supply of
The UK's NICE endorsed regular NHS funding for big-selling drugs from Roche and Sanofi, changing its mind in guidance for the multiple sclerosis and eczema drugs.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.